Prime

    Type your tag names separated by a space and hit enter

    Curcumin extract for prevention of type 2 diabetes.

    Abstract

    OBJECTIVE

    To assess the efficacy of curcumin in delaying development of type 2 diabetes mellitus (T2DM) in the prediabetic population.

    RESEARCH DESIGN AND METHODS

    This randomized, double-blinded, placebo- controlled trial included subjects (n = 240) with criteria of prediabetes. All subjects were randomly assigned to receive either curcumin or placebo capsules for 9 months. To assess the T2DM progression after curcumin treatments and to determine the number of subjects progressing to T2DM, changes in β-cell functions (homeostasis model assessment [HOMA]-β, C-peptide, and proinsulin/insulin), insulin resistance (HOMA-IR), anti-inflammatory cytokine (adiponectin), and other parameters were monitored at the baseline and at 3-, 6-, and 9-month visits during the course of intervention.

    RESULTS

    After 9 months of treatment, 16.4% of subjects in the placebo group were diagnosed with T2DM, whereas none were diagnosed with T2DM in the curcumin-treated group. In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (61.58 vs. 48.72; P < 0.01) and lower C-peptide (1.7 vs. 2.17; P < 0.05). The curcumin-treated group showed a lower level of HOMA-IR (3.22 vs. 4.04; P < 0.001) and higher adiponectin (22.46 vs. 18.45; P < 0.05) when compared with the placebo group.

    CONCLUSIONS

    A 9-month curcumin intervention in a prediabetic population significantly lowered the number of prediabetic individuals who eventually developed T2DM. In addition, the curcumin treatment appeared to improve overall function of β-cells, with very minor adverse effects. Therefore, this study demonstrated that the curcumin intervention in a prediabetic population may be beneficial.

    Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text

    • Grapherence [↓51 ↑32]

    Authors+Show Affiliations

    Chuengsamarn S
    ,

    Division of Endocrinology and Metabolism, Faculty of Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University, Nakornnayok, Thailand. somlukc@hotmail.com

    Rattanamongkolgul S
    ,
    Luechapudiporn R
    ,
    Phisalaphong C
    ,
    Jirawatnotai S

    Source

    Diabetes care 35:11 2012 Nov pg 2121-7

    MeSH

    Curcumin
    Diabetes Mellitus, Type 2
    Double-Blind Method
    Female
    Humans
    Male
    Middle Aged
    Plant Extracts
    Prediabetic State
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22773702

    Citation

    TY - JOUR T1 - Curcumin extract for prevention of type 2 diabetes. AU - Chuengsamarn,Somlak, AU - Rattanamongkolgul,Suthee, AU - Luechapudiporn,Rataya, AU - Phisalaphong,Chada, AU - Jirawatnotai,Siwanon, Y1 - 2012/07/06/ PY - 2012/7/6/aheadofprint PY - 2012/7/10/entrez PY - 2012/7/10/pubmed PY - 2013/4/18/medline SP - 2121 EP - 7 JF - Diabetes care JO - Diabetes Care VL - 35 IS - 11 N2 - OBJECTIVE: To assess the efficacy of curcumin in delaying development of type 2 diabetes mellitus (T2DM) in the prediabetic population. RESEARCH DESIGN AND METHODS: This randomized, double-blinded, placebo- controlled trial included subjects (n = 240) with criteria of prediabetes. All subjects were randomly assigned to receive either curcumin or placebo capsules for 9 months. To assess the T2DM progression after curcumin treatments and to determine the number of subjects progressing to T2DM, changes in β-cell functions (homeostasis model assessment [HOMA]-β, C-peptide, and proinsulin/insulin), insulin resistance (HOMA-IR), anti-inflammatory cytokine (adiponectin), and other parameters were monitored at the baseline and at 3-, 6-, and 9-month visits during the course of intervention. RESULTS: After 9 months of treatment, 16.4% of subjects in the placebo group were diagnosed with T2DM, whereas none were diagnosed with T2DM in the curcumin-treated group. In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (61.58 vs. 48.72; P < 0.01) and lower C-peptide (1.7 vs. 2.17; P < 0.05). The curcumin-treated group showed a lower level of HOMA-IR (3.22 vs. 4.04; P < 0.001) and higher adiponectin (22.46 vs. 18.45; P < 0.05) when compared with the placebo group. CONCLUSIONS: A 9-month curcumin intervention in a prediabetic population significantly lowered the number of prediabetic individuals who eventually developed T2DM. In addition, the curcumin treatment appeared to improve overall function of β-cells, with very minor adverse effects. Therefore, this study demonstrated that the curcumin intervention in a prediabetic population may be beneficial. SN - 1935-5548 UR - https://www.unboundmedicine.com/medline/citation/22773702/abstract/Curcumin_Extract_for_Prevention_of_Type_2_Diabetes_ L2 - http://care.diabetesjournals.org/cgi/pmidlookup?view=long&amp;pmid=22773702 ER -